Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alkermes initiates Phase III opioid dependence study
The clinical data from this study will form the basis of a supplemental new drug application (sNDA) to the FDA for Vivitrol for the treatment of opioid dependence,
The clinical data from this study will form the basis of a supplemental new drug application (sNDA) to the FDA for Vivitrol for the treatment of opioid dependence,
The test detects the presence of Heparin/PF-4 antibody, which is associated with patients at risk for heparin-induced thrombocytopenia (HIT), and is rapidly becoming a standard of care in
The RAMP cardiovascular product line includes Troponin I, CK-MB, Myoglobin and NT-proBNP Tests. The company is awaiting FDA 510(k) clearance before the NT-proBNP Test can be sold in
The TLN-232 trial is the second Phase II study to be initiated this year from Thallion’s oncology pipeline. The multi-centre open label Phase II trial will enroll up
The biomarkers were discovered through the use of Compugen’s Nucleic Acid Testing (NAT) discovery platform. A key component of the discovery effort was the integration of proprietary expression
The trial results indicated that the endovascular aortic repair (EVAR) procedure, using the Cook Zenith, is a safe and effective alternative to open surgical repair for the treatment
Aptuit Consulting, Aptuit’s global pharmaceutical drug development consultancy, managed the investigational new drug (IND)-enabling studies from manufacturing through IND submission and is engaged in the Phase I program.
Targanta is seeking approval of intravenous oritavancin in the EU for the treatment of complicated skin and soft tissue infections (cSSTI) caused by gram-positive bacteria, including methicillin-resistant Staphylococcus
Otsuka’s Tolvaptan is an investigational selective antagonist of the vasopressin V2 receptor, which is located predominantly in the kidney and plays a role in the regulation of fluid
Renato would then utilize Optimal Health Clinic’s infrastructure to introduce early detection diagnostic technologies. Renato considers this location to be an excellent launching model for the company’s future